JP2018537535A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537535A5
JP2018537535A5 JP2018549403A JP2018549403A JP2018537535A5 JP 2018537535 A5 JP2018537535 A5 JP 2018537535A5 JP 2018549403 A JP2018549403 A JP 2018549403A JP 2018549403 A JP2018549403 A JP 2018549403A JP 2018537535 A5 JP2018537535 A5 JP 2018537535A5
Authority
JP
Japan
Prior art keywords
compound according
ring
optionally substituted
fluorine
aliphatic group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018549403A
Other languages
English (en)
Japanese (ja)
Other versions
JP6810156B2 (ja
JP2018537535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/065865 external-priority patent/WO2017100601A1/en
Publication of JP2018537535A publication Critical patent/JP2018537535A/ja
Publication of JP2018537535A5 publication Critical patent/JP2018537535A5/ja
Application granted granted Critical
Publication of JP6810156B2 publication Critical patent/JP6810156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018549403A 2015-12-09 2016-12-09 Pad4のアザベンゾイミダゾール阻害剤 Active JP6810156B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264919P 2015-12-09 2015-12-09
US62/264,919 2015-12-09
PCT/US2016/065865 WO2017100601A1 (en) 2015-12-09 2016-12-09 Aza-benzimidazole inhibitors of pad4

Publications (3)

Publication Number Publication Date
JP2018537535A JP2018537535A (ja) 2018-12-20
JP2018537535A5 true JP2018537535A5 (enExample) 2020-01-23
JP6810156B2 JP6810156B2 (ja) 2021-01-06

Family

ID=59013635

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549403A Active JP6810156B2 (ja) 2015-12-09 2016-12-09 Pad4のアザベンゾイミダゾール阻害剤

Country Status (17)

Country Link
US (1) US9765093B2 (enExample)
EP (1) EP3386505B1 (enExample)
JP (1) JP6810156B2 (enExample)
KR (1) KR102683681B1 (enExample)
CN (1) CN108601770B (enExample)
AR (1) AR107030A1 (enExample)
AU (1) AU2016366405A1 (enExample)
BR (1) BR112018011633A2 (enExample)
CA (1) CA3007954A1 (enExample)
EA (1) EA201891347A1 (enExample)
ES (1) ES2830353T3 (enExample)
IL (1) IL259796A (enExample)
MX (1) MX2018006700A (enExample)
SG (1) SG11201804671SA (enExample)
TW (1) TW201726689A (enExample)
UY (1) UY37017A (enExample)
WO (1) WO2017100601A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201807021UA (en) * 2016-02-23 2018-09-27 Padlock Therapeutics Inc Heteroaryl inhibitors of pad4
US10703741B2 (en) 2016-07-27 2020-07-07 Padlock Therapeutics, Inc. Covalent inhibitors of PAD4
KR102502992B1 (ko) 2016-09-12 2023-02-24 패들락 테라퓨틱스, 인코포레이티드 Pad4의 헤테로아릴 억제제
EP3833440A1 (en) 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
ES2929200T3 (es) 2018-08-08 2022-11-25 Bristol Myers Squibb Co Tienopirroles sustituidos como inhibidores de PAD4
ES2956090T3 (es) * 2018-08-08 2023-12-13 Bristol Myers Squibb Co Inhibidores de bencimidazol de enzimas PAD
MX2021001471A (es) * 2018-08-08 2021-04-28 Bristol Myers Squibb Co Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
CN115298175B (zh) * 2020-02-06 2024-05-07 百时美施贵宝公司 可用作免疫抑制剂的大环pad4抑制剂
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
MX2022013615A (es) 2020-04-30 2022-11-16 Gilead Sciences Inc Inhibidores de macrociclo de peptidilarginina deiminasas.
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202233174A (zh) 2020-12-22 2022-09-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025199042A1 (en) * 2024-03-18 2025-09-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Methods for treating severe tuberculosis
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US8470819B2 (en) * 2008-11-03 2013-06-25 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
RU2611010C2 (ru) * 2012-07-26 2017-02-17 Глаксо Груп Лимитед 2-(Азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4

Similar Documents

Publication Publication Date Title
JP2018021051A5 (enExample)
JP2019537570A5 (enExample)
JP2013542261A5 (enExample)
JP2019516739A5 (enExample)
JP2016534063A5 (enExample)
JP2012513416A5 (enExample)
JP2012524056A5 (enExample)
JP2016518437A5 (enExample)
JP2017528503A5 (enExample)
JP2016528301A5 (enExample)
JP2014506907A5 (enExample)
JP2016503793A5 (enExample)
JP2017504635A5 (enExample)
JP2013510123A5 (enExample)
JP2016503797A5 (enExample)
JP2017517538A5 (enExample)
JP2016518328A5 (enExample)
JP2015520140A5 (enExample)
JP2020507589A5 (enExample)
JP2017501236A5 (enExample)
JP2015508092A5 (enExample)
JP2016505637A5 (enExample)
JP2019535723A5 (enExample)
JP2019505529A5 (enExample)
JP2016522254A5 (enExample)